Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.77 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.77 |
| ▸ | PTAFR | P25105 | 15/20 | 0.57 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8878960 | 0.89 | OPRK1 (0.74) | OPRK1PDE4DPTAFRGABRA1GABRA5 | |
| Etizolam SCHEMBL30665015 | 0.87 | OPRK1 (1.00) | OPRK1PDE4DPTAFRCYP3A4ALOX15 | |
| Etizolam SCHEMBL42920 | 0.87 | OPRK1 (1.00) | OPRK1PDE4DPTAFRCYP3A4ALOX15 | |
| SCHEMBL8928426 | 0.86 | GABRA1 (0.59) | OPRK1PDE4DPTAFRGABRA1GABRA5 | |
| SCHEMBL8928633 | 0.86 | OPRK1 (0.58) | OPRK1PDE4DPTAFRGABRA1GABRA5 | |
| SCHEMBL8928407 | 0.86 | OPRK1 (0.79) | OPRK1PDE4DPTAFRGABRA1GABRA5 | |
| SCHEMBL9663031 | 0.85 | PTAFR (0.62) | OPRK1PDE4DPTAFRGABRA1GABRA5 | |
| Etizolam SCHEMBL10869413 | 0.84 | OPRK1 (0.90) | OPRK1PDE4DPTAFRCYP3A4ALOX15 | |
| SCHEMBL8878112 | 0.82 | OPRK1 (0.79) | OPRK1PDE4DPTAFRCYP3A4ALOX15 | |
| SCHEMBL9864381 | 0.81 | OPRK1 (0.57) | OPRK1PDE4DPTAFRLMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388538-A1 | N,N-DIMETHYLTRYPTAMINE SALTS AND CRYSTALLINE SALT FORMS | ATAI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-0776892-A1 | THIENYLAZOLE COMPOUND AND THIENOTRIAZOLODIAZEPINE COMPOUND | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388538-A1 | N,N-DIMETHYLTRYPTAMINE SALTS AND CRYSTALLINE SALT FORMS | SLC6A4, SLC6A2, SLC18A2 | OPRK1 159/4885PDE4D 626/4885PTAFR 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.